Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 96

    1.

    Summary of worldwide pediatric malignancies reported after exposure to etanercept.

    McCroskery P, Wallace CA, Lovell DJ, Stryker S, Chernyukhin N, Blosch C, Zack DJ.

    Pediatr Rheumatol Online J. 2010 Jun 14;8:18.

    PMID:
    20546618
    [PubMed]
    Free PMC Article
    2.

    Final Report on Carcinogens Background Document for Styrene.

    National Toxicology Program.

    Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.

    PMID:
    20737009
    [PubMed - as supplied by publisher]
    3.

    Final Report on Carcinogens Background Document for Formaldehyde.

    National Toxicology Program.

    Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.

    PMID:
    20737003
    [PubMed - as supplied by publisher]
    4.

    Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration.

    Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A.

    Arthritis Rheum. 2010 Aug;62(8):2517-24.

    PMID:
    20506368
    [PubMed - indexed for MEDLINE]
    Free Article
    5.

    Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.

    Silva F, Seo P, Schroeder DR, Stone JH, Merkel PA, Hoffman GS, Spiera R, Sebastian JK, Davis JC Jr, St Clair EW, Allen NB, McCune WJ, Ytterberg SR, Specks U; Wegener's Granulomatosis Etanercept Trial Research Group.

    Arthritis Rheum. 2011 Aug;63(8):2495-503. doi: 10.1002/art.30394.

    PMID:
    21484770
    [PubMed - indexed for MEDLINE]
    6.

    Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.

    Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, Specks U, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune WJ, Ytterberg SR, Allen NB, Hoffman GS; Wegener's Granulomatosis Etanercept Trial Research Group.

    Arthritis Rheum. 2006 May;54(5):1608-18.

    PMID:
    16646004
    [PubMed - indexed for MEDLINE]
    Free Article
    7.

    Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?

    Cron RQ, Beukelman T.

    Pediatr Rheumatol Online J. 2010 Aug 16;8:23.

    PMID:
    20712883
    [PubMed]
    Free PMC Article
    8.

    Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

    Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.

    Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.

    PMID:
    17083854
    [PubMed - indexed for MEDLINE]
    Free Article
    9.

    [Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009].

    Horneff G, Hospach T, Dannecker G, Föll D, Haas JP, Girschick HJ, Huppertz HI, Keitzer R, Laws HJ, Michels H, Minden K, Trauzeddel R.

    Z Rheumatol. 2010 Aug;69(6):561-7. German.

    PMID:
    20174926
    [PubMed - indexed for MEDLINE]
    10.

    Pediatric stroke among Hong Kong Chinese subjects.

    Chung B, Wong V.

    Pediatrics. 2004 Aug;114(2):e206-12.

    PMID:
    15286258
    [PubMed - indexed for MEDLINE]
    Free Article
    11.

    Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.

    Henney HR 3rd, Chez M.

    Paediatr Drugs. 2009;11(6):397-406. doi: 10.2165/11316090-000000000-00000.

    PMID:
    19877725
    [PubMed - indexed for MEDLINE]
    12.

    Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.

    Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, Whitmore JB, White BW.

    J Rheumatol. 2006 May;33(5):854-61. Epub 2006 Mar 15.

    PMID:
    16541481
    [PubMed - indexed for MEDLINE]
    13.

    Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.

    Schiff MH, Yu EB, Weinblatt ME, Moreland LW, Genovese MC, White B, Singh A, Chon Y, Woolley JM.

    Drugs Aging. 2006;23(2):167-78.

    PMID:
    16536638
    [PubMed - indexed for MEDLINE]
    14.

    Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications.

    Gottlieb AB, Gordon K, Giannini EH, Mease P, Li J, Chon Y, Maddox J, Weng HH, Wajdula J, Lin SL, Baumgartner SW.

    J Drugs Dermatol. 2011 Mar;10(3):289-300.

    PMID:
    21369647
    [PubMed - indexed for MEDLINE]
    15.

    Challenges in the management of juvenile idiopathic arthritis with etanercept.

    Pain CE, McCann LJ.

    Biologics. 2009;3:127-39. Epub 2009 Jul 13.

    PMID:
    19707402
    [PubMed]
    Free PMC Article
    16.

    Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.

    Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH; Pediatric Rheumatology Collaborative Study Group.

    Arthritis Rheum. 2008 May;58(5):1496-504.

    PMID:
    18438876
    [PubMed - indexed for MEDLINE]
    Free Article
    17.
    18.

    Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.

    [No authors listed]

    Drugs R D. 2003;4(5):312-9. Review.

    PMID:
    12952502
    [PubMed - indexed for MEDLINE]
    19.

    A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

    Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

    Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

    PMID:
    17049139
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.

    Théophile H, Schaeverbeke T, Miremont-Salamé G, Abouelfath A, Kahn V, Haramburu F, Bégaud B.

    Drug Saf. 2011 Jul 1;34(7):577-85. doi: 10.2165/11590200-000000000-00000.

    PMID:
    21663333
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk